Research use only. Nothing on this page is medical advice.
GHRH peptides are synthetic versions of growth hormone-releasing hormone. They bind the GHRH receptor on the pituitary and raise your own growth hormone (GH) and IGF-1.
Only one is FDA-approved today: tesamorelin, for fat in HIV lipodystrophy (1). Where the others stand:
- Sermorelin: approvals withdrawn in 2009 (1)
- CJC-1295: two controlled trials in healthy adults (2)
- CJC-1295 without DAC: no peer-reviewed human studies (1)
Jump to the comparison, the trials, GHRH vs GHRP, safety or sermorelin sellers.
What is a GHRH peptide?
GHRH is the signal your hypothalamus sends to the pituitary to release a pulse of GH. Natural GHRH has 44 amino acids. Sermorelin is the first 29 of them and keeps the biological activity (3). Tesamorelin is a stabilized analog of the full 44-amino-acid hormone (4). A GHRH peptide tells the pituitary to make more of its own GH.
GHRH peptides compared
| Peptide | What it is | Human evidence | Status |
|---|---|---|---|
| 1Tesamorelin | Stabilized analog of 44-amino-acid GHRH. Half-life about 26 to 38 minutes (1) | Randomized trials in HIV lipodystrophy, plus trials in healthy men and type 2 diabetes (1, 4, 5) | FDA-approved since November 2010. Egrifta WR approved March 2025 (1) |
| 2Sermorelin | GHRH 1-29, 29 amino acids (3) | Pediatric GH-deficiency diagnosis and treatment studies (3) | Geref approvals withdrawn 18 June 2009, not for safety or effectiveness (1) |
| 3CJC-1295 with DAC | Long-acting analog bound to albumin. Half-life 5.8 to 8.1 days (2) | Two randomized, placebo-controlled trials in healthy adults, 28 and 49 days (2) | Not approved |
| 4CJC-1295 without DAC (Mod GRF 1-29) | Modified GRF 1-29 without the albumin-binding DAC | No peer-reviewed human studies found in a 2026 review (1) | Not approved |
| 5[Nle27]GHRH(1-29)-NH2 | GHRH 1-29 analog used in older research | 16-week trial in 19 adults aged 55 to 71 (6) | Research only |
What do the human trials show?
The strongest data belong to tesamorelin and CJC-1295.
How to read the table. Limited: small human trials. Mice, Animals: lab or animal work only. Review: a summary of other studies.
| Study | Model | What it reported | Watch-out |
|---|---|---|---|
| People | |||
| 1Teichman, 2006Two randomized, double-blind, placebo-controlled trials | Healthy adults aged 21 to 61, CJC-1295 by injection | LimitedGH rose 2 to 10-fold for at least 6 days and IGF-I 1.5 to 3-fold for 9 to 11 days. No serious adverse reactions (2) | Healthy volunteers, short trials, no outcome endpoints |
| 2Stanley, 2011Non-randomized, before and after | 13 healthy men, 2 weeks of tesamorelin | LimitedMean overnight GH rose 0.5 µg/L (P = .004) and IGF-I rose 181 µg/L. Insulin-stimulated glucose uptake didn’t change (4) | No control group, 13 men |
| 3Clemmons, 2017Randomized, placebo-controlled, 12 weeks | 53 people with type 2 diabetes | LimitedInsulin response, fasting glucose and HbA1c didn’t change. Total and non-HDL cholesterol fell in the higher-dose group (5) | A safety study, not an efficacy trial |
| 4Khorram, 1997Single-blind, randomized, placebo-controlled | 19 adults aged 55 to 71, 16 weeks of a GHRH analog | LimitedNocturnal GH and IGF-I rose. Lean mass and insulin sensitivity rose in men only. Sleep quality was unaffected, and transient hyperlipidemia was the only side effect (6) | 19 people, and the women showed fewer benefits |
| 5Popovic, 1995Controlled test, 23 people | GHRH, GHRP-6 or both given to 11 healthy controls and 12 patients | LimitedIn controls, GH after both (3,771.5) exceeded the sum of each alone (1,918.5). The synergy vanished in patients with a disconnected hypothalamus and pituitary (7) | Short IV tests of GH release, not treatment trials |
| Animals | |||
| 6Dulce, 2025Review of animal studies | Cardiomyopathy models in small and large animals | ReviewGHRH and its agonists showed receptor-mediated heart protection in preclinical models (8) | Translation is limited by route of administration and GH/IGF-1 side effects |
| 7Ren, 2026Narrative review | Heart and brain disease models, MR-409 | ReviewMR-409 eased vascular calcification, aided heart repair after infarction and protected against stroke in animals, independent of GH and IGF-1 (9) | Animal models only |
| 8Shao, 2026Mouse study | Mice with limb ischemia | MiceNew long-acting analogs showed serum half-lives above 24 hours and improved limb perfusion (10) | A chemistry paper, not a safety study |
| Independent reviews | |||
| 9Dominikowski, 2026Narrative review | GH and IGF-1 axis peptides | ReviewGrades tesamorelin as regulatory-grade evidence and CJC-1295 without DAC as no peer-reviewed human studies (1) | Narrative reviews don’t standardize study selection |
| 10Vasylieva, 2026Narrative review, 76 studies | Peptides in sexual medicine | ReviewGH secretagogues reliably raise GH and IGF-1, but evidence for function, performance or quality of life is limited (11) | Covers a whole class of peptides |
GHRH analogs reliably raise GH and IGF-I in people. What that does for body composition, sleep or aging isn’t established outside tesamorelin’s approved use. The one trial that measured sleep found no change (6).
GHRH vs GHRP
GHRH peptides act on the GHRH receptor. GHRP peptides such as ipamorelin and GHRP-6 mimic ghrelin and act on a different receptor, GHS-R1a (1). In the 1995 test, GH release after GHRH plus GHRP-6 beat the sum of each alone, but only when the hypothalamus and pituitary were connected (7).
That is an acute lab result. A 2026 review calls stacking GHRH and GHRP products anecdotal and says controlled evidence of benefit is limited (1). See our ipamorelin vs sermorelin and CJC-1295 and ipamorelin guides.
GHRH peptides vs growth hormone
Injected GH is the finished hormone. GHRH analogs work upstream, so the body’s own feedback, including somatostatin, still limits GH release (1). In healthy men, tesamorelin raised IGF-I while insulin-stimulated glucose uptake stayed unchanged (4).
Beyond the pituitary: engineered GHRH agonists
GHRH receptors also sit outside the pituitary, in heart, blood vessel and nerve tissue (9). Schally’s group built successive agonist series, and in animals these promoted tissue regeneration, improved heart function and protected pancreatic islets. The same group also develops GHRH antagonists as anticancer agents, because tumor cells carry GHRH receptors (12). We found no human trials of these engineered agonists in our sources.
GHRH peptide safety and side effects
- CJC-1295 trials in healthy adults reported no serious adverse reactions (2).
- The 16-week GHRH analog trial reported transient hyperlipidemia as its only side effect (6).
- For tesamorelin, reviews list injection-site reactions, joint and muscle symptoms, and glucose monitoring, and flag elevated IGF-1 as a theoretical cancer concern (1).
- Non-approved GHRH peptides have no long-term safety data, and safety data across peptide classes are limited by short follow-up and small samples (1, 11).
Are GHRH peptides legal?
Tesamorelin is approved for HIV lipodystrophy. Sermorelin’s approvals were withdrawn in 2009 (1). The rest aren’t approved. WADA’s 2026 list prohibits GHRH and its analogues, naming CJC-1295, sermorelin and tesamorelin (13), and a 2021 study built urine tests for them with detection limits near 1 ng/mL or lower (14). A research-use-only label is a sales category and says nothing about contents.
GHRH peptide dosage
We don’t list doses. The doses in the trials above were set for each study and aren’t recommendations. No dose is established for the non-approved peptides, and a 2026 review labels forum dosing tables behavioral data (1).
How to check a GHRH peptide vial
GHRH peptides are large molecules, so a report should show mass spectrometry. Elite Edge’s sermorelin report measured 3355.92 Da against 3355.82 expected, and its CJC-1295 without DAC blend report measured 3365.98 against 3365.89 (15, 16). Check that the lot number matches your vial and that the report states net content, not only purity. Our guide to verifying a peptide COA explains each line.
| Seller | Lot report | Watch-out |
|---|---|---|
| 1Amino Club | ILS Laboratories, lot SER0002, tested 22 Oct 2026. Purity 99.41% by HPLC, 10.43 mg measured on a 10 mg label (17) | Identity is an HPLC match, with no mass spectrum named |
| 2Elite Edge | MZ Biolabs, lot 2026-07-22. Purity 99.64%, mass 3355.92 Da against 3355.82 expected (15, 18) | The report gives no content in mg |
| 3SwissChems | 2 mg vial. The only report linked is titled heavy metal (19) | No purity or content report on the page |
Amino Club
Sermorelin 10 mg · $59.99 ($6.00 per mg)
- Public lot report from ILS Laboratories (ISO/IEC 17025) on the product page
- Free standard shipping over $100, same-day dispatch before 3 PM ET
Elite Edge Biotech
Sermorelin 10 mg · $49 ($4.90 per mg)
- MZ Biolabs certificate with mass spectrometry identity
- Free US shipping over $200
SwissChems
Sermorelin 2 mg · $25.95 ($12.98 per mg)
- Same-day US shipping before 12 PM EST
- 30-day returns on unopened products
More on sermorelin sellers is in sermorelin peptide for sale, and our CJC-1295 without DAC guide covers that peptide. Compare more sellers in best peptide vendors.
GHRH peptides FAQ
What is a GHRH peptide?
A GHRH peptide is a synthetic version of growth hormone-releasing hormone. It binds the GHRH receptor on the pituitary and raises your own growth hormone and IGF-1. Examples are sermorelin, CJC-1295 and tesamorelin.
What is the difference between GHRH and GHRP?
GHRH peptides act on the GHRH receptor. GHRP peptides, such as ipamorelin and GHRP-6, mimic ghrelin and act on the GHS-R1a receptor. In a 1995 test, giving GHRH with GHRP-6 released more GH than the sum of each alone.
Are GHRH peptides the same as growth hormone?
No. Growth hormone is the finished hormone. GHRH peptides signal the pituitary to release its own, so the body’s feedback still limits the release.
What is GHRH 1-29?
The first 29 amino acids of the 44-amino-acid natural hormone. Sermorelin is GHRH 1-29, and CJC-1295 is a modified version of it.
Which GHRH peptides are FDA approved?
Only tesamorelin, approved in November 2010 for fat in HIV lipodystrophy. Sermorelin’s approvals were withdrawn in June 2009 after the maker stopped selling it.
Which GHRH peptide has the most evidence?
Tesamorelin. It has randomized trials in HIV lipodystrophy and trials in healthy men and in type 2 diabetes. CJC-1295 without DAC has no peer-reviewed human studies.
Do GHRH peptides work for anti-aging or sleep?
Not shown. In a 16-week trial in adults aged 55 to 71, a GHRH analog raised GH and IGF-I and lean mass in men, but sleep quality was unaffected.
Are GHRH peptides banned in sport?
Yes. WADA’s 2026 list prohibits GHRH and its analogues, naming CJC-1295, sermorelin and tesamorelin.
What is GHRP-2?
GHRP-2 is a growth hormone releasing peptide that mimics ghrelin and acts on GHS-R1a. It belongs to the GHRP class, not the GHRH class.
Sources
Show references (19)Hide references
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. Source
- Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. Source
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999. Source
- Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011. Source
- Clemmons DR, et al. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One 2017. Source
- Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. Source
- Popovic V, et al. Blocked GHRP-6-induced GH secretion and absence of the synergic action of GHRP-6 plus GHRH in patients with hypothalamopituitary disconnection. J Clin Endocrinol Metab 1995. Source
- Dulce R, et al. Growth hormone-releasing hormone signaling and manifestations within the cardiovascular system. Rev Endocr Metab Disord 2025. Source
- Ren H, et al. Therapeutic potential of growth hormone-releasing hormone analogues in cardiovascular and cerebrovascular diseases: mechanisms and preclinical evidence. Front Pharmacol 2026. Source
- Shao HD, et al. Peptidomimetic long-acting growth hormone-releasing hormone agonists promote tissue perfusion in hindlimb ischemia. J Med Chem 2026. Source
- Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety. Sex Med Rev 2026. Source
- Schally AV, et al. The development of growth hormone-releasing hormone analogs: therapeutic advances in cancer, regenerative medicine, and metabolic disorders. Rev Endocr Metab Disord 2025. Source
- WADA. The 2026 Prohibited List, section S2.2.4. Source
- Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal 2021. Source
- MZ Biolabs certificate for Elite Edge, sermorelin 10 mg, lot 2026-07-22. Source
- MZ Biolabs certificate for Elite Edge, ipamorelin with CJC-1295 no DAC, lot 2026-05-28. Source
- Amino Club. Sermorelin 10 mg product page with the released lot report (ILS Laboratories, lot SER0002). Source
- Elite Edge Biotech. Sermorelin 10mg product page. Source
- SwissChems. Sermorelin 2mg product page and linked report. Source